-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January 18, 2021 // -- Lilly Pharmaceuticals of the United States recently announced encouraging results from a small study on the experimental drug donanemab for Alzheimer's disease.
Photo Source: Medicalxpress.com The two-year Phase 2 clinical trial included 272 patients with mild to moderate Alzheimer's symptoms, the New York Times reported. The rate of mental decline in patients who were infused with the experimental drug around them slowed by 32 percent, and after 6-12 months of treatment with the donanemab drug, the patient's body no longer carried β amyloid plaques, a hallmark of Alzheimer's disease.
However, the findings have not yet been reviewed by other researchers and have not been published in any form, and the main side effects of the drug are common in patients taking experimental monoclonal antibodies to treat Alzheimer's disease, i.e. fluid build-up in the brain occurs in nearly 30 percent of patients, but most do not show symptoms and can only be observed in brain imaging.
the results of the current trial need to be replicated, dr. Michael Weiner, a scientist at the University of California, said that even so, the development of a new drug for Alzheimer's disease, donanemab, is good news for many patients and families.
() Original source: The original source: An investment drug for Alzheimer's disease show promiseDrug maker Eli Lilly on Monday announceded by the profiled forward results from from a small study of an agency Alzheimer's disease drug drug called donanemab. The two-year, phase 2 clinical trial included 272 patients with mild-to-moderate Alzheimer's disease symptoms. The company said that patients who received the drug by infusion every four weeks had a 32 percent slower rate of mental decline than those who were given a placebo, The New York Times reported. After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques that are hallmarks of Alzheimer disease, according to Daniel Skovronsky, M.D., the company's chief scientific officer.......
